AcuraStem

AcuraStem is a near-to-clinic, patient-based therapeutics company advancing treatments for ALS, FTD and additional neurodegenerative indications.

AcuraStem harnesses advanced cellular reprogramming and artificial intelligence technologies to transform the standard of care for neurodegenerative diseases through patient-specific treatment. Go to acurastem.com to find out more.

12/24/2025

In 2025, support from clinicians, advocates, and research partners helped AcuraStem use iNeuroRx® to expand patient-derived ALS and FTD models and keep its antisense programs, like UNC13A and SYF2, moving toward clinical trials.

Thank you for backing patient-based science focused on faster, more effective treatments for people living with ALS and FTD. Warm holiday wishes and a hopeful new year from team at AcuraStem.

12/18/2025

iNeuroRx® builds cellular disease models derived from patients for ALS and FTD, so AcuraStem can study human neurodegeneration directly in the lab, find high-value targets and design antisense therapies such as its UNC13A program.

Explore this cutting-edge technology at: acurastem.com

12/08/2025

Be part of the next generation of neurodegenerative research.
Stay informed on new discoveries, technology updates, and partnership opportunities.

Keep up-to-date with AcuraStem at acurastem.com/ -form

12/05/2025

AcuraStem - ALS drug discovery built directly in neurons derived from patients.

Most neurodegenerative research still starts in models that don’t reflect the biology of the people they’re meant to help. At AcuraStem, we take a different approach. Our iNeuroRX® platform uses patient-derived neurons to identify therapies grounded in human biology from the outset. That means fewer dead ends, and more meaningful progress for ALS and other neurodegenerative diseases.

Meet the team today at the 2025 ALS/MND conference in San Diego.
AcuraStem is on-site and ready to connect.

Find out more at acurastem.com

12/02/2025

AcuraStem is developing treatments for ALS and FTD using patient-derived cell models and our iNeuroRx® technology platform. Studying disease in neurons from real patients helps us discover targeted therapies that are more likely to work across diverse forms of neurodegenerative disease.

Learn more: acurastem.com

11/27/2025

Happy Thanksgiving from all of us at AcuraStem! Wishing you a day filled with gratitude, joy and meaningful moments with loved ones.

11/24/2025

We’re grateful this holiday season for our dedicated colleagues driving discovery at AcuraStem. Their passion and innovation bring us closer to life-changing therapies every day.

Get to know them: acurastem.com/about-us -section

11/21/2025

We’re transforming neuroscience innovation into real-world therapies, built on deep biological understanding and shaped with the patient in mind. The result is treatments that are faster, smarter and more precise.
Discover more: acurastem.com

11/19/2025

Traditional drug discovery often falls short because animal models can’t fully mirror human disease. AcuraStem is changing that by developing patient-derived models that reveal the true biology of neurodegeneration, paving the way for more effective treatments.

Learn more: acurastem.com

10/06/2025

Most neurodegenerative research still starts in models that don’t reflect the biology of the people they’re meant to help.

At AcuraStem, we take a different approach. Our iNeuroRX® platform uses patient-derived neurons to identify therapies grounded in human biology from the outset.

That means fewer dead ends, and more meaningful progress for ALS and other neurodegenerative diseases. Meet us at the 2025 NEALS Consortium Meeting in Clearwater, FL, October 7 - 10.

AcuraStem CEO Sam Alworth will be on-site and ready to connect.

Find out more at acurastem.com

08/26/2025

AcuraStem at Pre-SPARK

Tomorrow AcuraStem co-founders Sam Alworth and Dr. Justin Ichida will speak on the Faculty Spinout Panel at USC’s Pre-SPARK program, highlighting how academic breakthroughs can advance toward clinical application.

The panel is part of Pre-SPARK’s mission to support researchers navigating the complex path from lab discovery to therapeutic development, bringing together USC, CHLA, and industry experts to remove barriers to commercialization.

🧬 August 27 | 3–5 PM
📍 MCB 101, USC
🔗 https://sites.usc.edu/transformativedelivery/usc-spark

07/22/2025

📅 TODAY!: Don’t miss Sam Alworth, AcuraStem’s CEO, presenting “Using the iNeuroRX® Technology Platform to Develop Disease-Modifying Treatments for ALS and FTD: Spotlight on UNC13A Candidate AS-241” at Frontiers in Neuroscience: Emerging Biology and Therapeutics, a free virtual symposium.

💻 Catch the talk Today at 11:20–11:55 AM PT via Zoom. Registration is free and open now. 🔗 There's still time to Register here 👇 :

https://lnkd.in/e9Q5ik4e

🧠 Sam will highlight how AcuraStem’s iNeuroRX® platform enables the discovery of potent, durable, and well-tolerated A*O drug candidates by modeling ALS and FTD using patient-derived cells, with a focus on AS-241, a promising UNC13A-targeting therapy.

*O

Address

Monrovia, CA

Website

http://www.acurastem.com/

Alerts

Be the first to know and let us send you an email when AcuraStem posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to AcuraStem:

Shortcuts

Want your practice to be the top-listed Clinic in Monrovia?